4.7 Review

L-FABP: A novel biomarker of kidney disease

期刊

CLINICA CHIMICA ACTA
卷 445, 期 -, 页码 85-90

出版社

ELSEVIER
DOI: 10.1016/j.cca.2015.03.017

关键词

Liver-type fatty acid-binding protein; Fatty acid; Acute kidney injury; Chronic kidney disease

资金

  1. National Basic Research Program of China 973 Program [2012CB517600, 2012CB517602]
  2. HongKong, Macao and Taiwan Science & Technology Cooperation Program of China [2014DFT30090]
  3. National Natural Science Foundation of China [81102700, 81373865, 81370794]
  4. National Key Technology RD Program [2011BAI10B08]
  5. Science and Technology Commission of Shanghai Municipality, China [12401906400, 13401906100, 14140903200]
  6. Shanghai Health Bureau [ZYSNXD012-RC-ZXY017]

向作者/读者索取更多资源

Human liver-type fatty acid-binding protein (hL-FABP), which is found in both the normal and the diseased human kidney, has been observed to bind free fatty acids. Recently, the predictive and prognostic value of L-FABP in kidney diseases has attracted considerable attention. Numerous studies have demonstrated that L-FABP is a promising biomarker of several kidney diseases, and it has also been shown to attenuate renal injury. We performed a literature review regarding the ability of L-FABP to identify patients at risk of developing kidney diseases, including acute kidney injury (AKI) and chronic kidney disease (CKD) and to protect the kidneys in the course of kidney disease. (C) 2015 Elsevier B.V. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据